Insider Buying: Gain Therapeutics, Inc. (NASDAQ:GANX) CEO Purchases 4,000 Shares of Stock
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) CEO Eric I. Richman purchased 4,000 shares of the stock in a transaction dated Thursday, May 19th. The shares were acquired at an average price of $2.71 per share, for a total transaction of $10,840.00. Following the acquisition, the chief executive officer now directly owns 205,991 shares of the company’s stock, valued at approximately $558,235.61. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
GANX traded up $0.05 during trading on Monday, reaching $2.81. 49,864 shares of the stock traded hands, compared to its average volume of 119,699. The stock has a market cap of $33.39 million, a price-to-earnings ratio of -2.26 and a beta of 0.35. Gain Therapeutics, Inc. has a fifty-two week low of $2.53 and a fifty-two week high of $11.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.63 and a quick ratio of 14.78. The stock’s 50-day simple moving average is $3.65 and its two-hundred day simple moving average is $4.78.
Gain Therapeutics (NASDAQ:GANX – Get Rating) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. Gain Therapeutics had a negative return on equity of 40.43% and a negative net margin of 7,212.75%. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.06 million. Research analysts anticipate that Gain Therapeutics, Inc. will post -1.33 earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the business. UBS Group AG lifted its position in shares of Gain Therapeutics by 64.4% in the third quarter. UBS Group AG now owns 6,740 shares of the company’s stock worth $51,000 after buying an additional 2,640 shares during the last quarter. Advisor Group Holdings Inc. acquired a new stake in shares of Gain Therapeutics in the fourth quarter worth about $54,000. Jane Street Group LLC acquired a new stake in shares of Gain Therapeutics in the first quarter worth about $48,000. Citadel Advisors LLC acquired a new stake in shares of Gain Therapeutics in the fourth quarter worth about $70,000. Finally, Millennium Management LLC acquired a new stake in shares of Gain Therapeutics in the fourth quarter worth about $84,000. 8.89% of the stock is owned by institutional investors.
A number of research analysts have recently weighed in on GANX shares. HC Wainwright started coverage on Gain Therapeutics in a report on Tuesday, March 29th. They set a “buy” rating and a $12.00 price target on the stock. B. Riley lowered their price target on Gain Therapeutics from $16.00 to $11.00 in a report on Monday. Finally, Zacks Investment Research raised Gain Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 1st.
About Gain Therapeutics (Get Rating)
Gain Therapeutics, Inc, a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.
Receive News & Ratings for Gain Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gain Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.